Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer

Prostate cancer is the most commonly diagnosed cancer but the management of advanced prostate cancer remains a therapeutic challenge, despite the survival benefits imparted by several therapeutic discoveries targeting different molecular pathways. The mechanisms of resistance to androgen deprivation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2023-10, Vol.129 (7), p.1050-1060
Hauptverfasser:	Conteduca, Vincenza, Brighi, Nicole, Schepisi, Giuseppe, De Giorgi, Ugo
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/248 692/4028/67/589/466 Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - genetics Androgen Antagonists - therapeutic use Androgen receptors Androgens Biomedical and Life Sciences Biomedicine Cancer Research Drug Resistance Epidemiology Genomics Humans Immune system Immunoregulation Immunotherapy Male Metastases Microenvironments Molecular Medicine Neoantigens Oncology Patients Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Receptors, Androgen - genetics Receptors, Androgen - metabolism Review Article Tumor Microenvironment - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!